Ribon Therapeutics Is A Clinical Stage Biotechnology Company Based In Cambridgemassachusettsfounded In 2015It Focused On Developing Small Molecule Therapeutics That Target Stress Activated Pathways In Cancer And Inflammatory Diseasesthe Company Utilized Its Proprietary Beaconplatform To Discover Inhibitors Of Nadutilizing Enzymesparticularly Mono Adp Ribosyltransferaseswhich Are Important In Cellular Stress Responses Ribon S Clinical Programs Included Rbn 2397A Selective Parp7 Inhibitor For Solid Tumorsand Rbn 3143A Parp14 Inhibitor For Moderate To Severe Atopic Dermatitisboth Therapies Were Designed As Oralsmall Molecule Treatments With The Potential To Be First In Classthe Company Engaged In Strategic Partnershipsincluding A Significant Investment From Pfizerand Aimed To Address Unmet Medical Needs In Oncology And Inflammatory Diseases
